John E. Wagner

John E. Wagner

Pediatrics | Pediatric Hematology Oncology

Journey Clinic Riverside East 9th
Floor 2450 Riverside Ave
Minneapolis, MN 55454

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 181 publications

Tracking Cytopenias in FANCA-deficient Fanconi Anemia.

Tracking Cytopenias in FANCA-deficient Fanconi Anemia.

Journal: medRxiv : the preprint server for health sciences

Published: December 25, 2025

"It's All My Fault": Responding to Patient Self-Blame in Serious Illness Care.

"It's All My Fault": Responding to Patient Self-Blame in Serious Illness Care.

Journal: Journal of palliative medicine

Published: November 21, 2025

CSF GAG non-reducing ends in MPS IH after peripheral and brain-penetrating therapies: A model comparing IV non-targeted ERT and HCT.

CSF GAG non-reducing ends in MPS IH after peripheral and brain-penetrating therapies: A model comparing IV non-targeted ERT and HCT.

Journal: Molecular therapy. Advances

Published: August 27, 2025

G-quadruplexes as a source of vulnerability in BRCA2-deficient granule cell progenitors and medulloblastoma.

G-quadruplexes as a source of vulnerability in BRCA2-deficient granule cell progenitors and medulloblastoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 25, 2025

Increased Vascular Age in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation: Results of a Single-Center Descriptive Analysis.

Increased Vascular Age in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation: Results of a Single-Center Descriptive Analysis.

Journal: Transplantation and cellular therapy

Published: July 29, 2025

Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.

Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer.

Journal: Journal for immunotherapy of cancer

Published: July 10, 2025

Analysis of BRCA1, BRCA2 and PALB2 related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

Analysis of BRCA1, BRCA2 and PALB2 related Fanconi anemia identifies scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

Journal: medRxiv : the preprint server for health sciences

Published: June 26, 2025

Research Communication: Prevalence of Asymptomatic Premalignant Oesophageal Lesions in Patients With Fanconi Anaemia.

Research Communication: Prevalence of Asymptomatic Premalignant Oesophageal Lesions in Patients With Fanconi Anaemia.

Journal: Alimentary pharmacology & therapeutics

Published: June 13, 2025

BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes.

Journal: American journal of human genetics

Published: May 15, 2025

CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantation: A descriptive genetic association study.

CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantation: A descriptive genetic association study.

Journal: Medicine

Published: March 24, 2025

Selecting Appropriate Clinical Trial Endpoints for Geroscience Trials: A Path Towards Consensus.

Selecting Appropriate Clinical Trial Endpoints for Geroscience Trials: A Path Towards Consensus.

Journal: Research square

Published: February 24, 2025

Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies.

Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 29, 2025

Showing 1-12 of 181

Last Updated: 09/26/2026